Portuguese 
English 
Spanish 
4 min of reading 
0 comments 
UCL Study in Nature Communications Maps Epoxy-Oxylipins and Shows that Blocking sEH Accelerates Pain Resolution Without Suppressing Immunity.
Researchers at University College London reported in the journal Nature Communications the identification of a natural mechanism that curbs inflammation. The work, conducted entirely in humans, maps the action of epoxy-oxylipins, small molecules derived from fat that help turn off the exaggerated immune response. According to UCL, the strategy preserves the body’s defense and accelerates the resolution of pain. The findings pave the way for safer therapies against chronic inflammation and diseases such as rheumatoid arthritis.
The study coordinated by UCL, with participation from King’s College London, the University of Oxford, Queen Mary University of London, and the National Institute of Environmental Health Sciences in the United States, describes a cellular “switch” that limits inflammatory damage. According to UCL, by increasing the availability of epoxy-oxylipins, the body can contain the expansion of immune cells without suppressing overall immunity.
The research used the inhibitor GSK2256294, which blocks the enzyme soluble epoxide hydrolase (sEH) responsible for degrading these protective molecules. The blockade raised levels of epoxy-oxylipins and accelerated pain improvement, while maintaining the body’s overall defense capacity, according to the article.
-
Melting of Arctic ice has exposed shallow waters to more sunlight and accelerated a process that reduces nitrate, an essential nutrient for sustaining the marine food chain.
-
YouTube watches videos made by artificial intelligence, activates automatic labeling for realistic content, and enters the race for digital transparency.
-
Panasonic enters the era of electric bicycles with the new Xealt L3 equipped with high-performance reinforced axles, hydraulic disc brakes, more durable urban tires, and a range of up to 90 km with a recharge time of just 4 hours.
-
Scientists from Brazil, France, and the United Kingdom warn that the flow of the Amazon River has increased by up to 60% in floodable areas and may affect fish, floodplains, and riverside communities.
Olivia Bracken, the first author, stated that directing this natural pathway could lead to safer treatments, restoring immune balance. Derek Gilroy, also an author, emphasized that this is the first time the activity of these molecules has been mapped in humans during an inflammatory process.
Study in Humans Maps the Biological Brake of Epoxy-Oxylipins
Scientists induced a controlled inflammation in healthy volunteers by applying an injection of ultraviolet radiation-inactivated E. coli bacteria to their forearms. The reaction generated pain, redness, heat, and swelling, allowing real-time monitoring of immune cell behavior.
The participants were divided into two groups. One received GSK2256294 before the onset of inflammation, while the other took the drug four hours after symptoms appeared, simulating a delayed treatment.
According to UCL, the aim was to compare a preventive approach with a therapeutic one and to observe whether an increase in epoxy-oxylipins would accelerate resolution. In both scenarios, researchers were able to measure cellular and clinical signs of response and recovery.
Blocking the sEH Enzyme Raises Epoxy-Oxylipins and Reduces Intermediate Monocytes
By inhibiting sEH, the body retains more epoxy-oxylipins, including 12,13-EpOME, which acted to turn off the protein signal p38 MAPK, crucial in the transformation of inflammatory cells. This shutdown acted as a brake, preventing the escalation of the immune response.
The results showed a significant reduction of intermediate monocytes in the blood and tissues, cells that, when elevated, keep inflammation active. According to a note from UCL, containing this subgroup helps shorten the inflammatory episode.
There was also an acceleration of pain resolution reported by volunteers, without significant changes in external signs such as redness and swelling. This indicates a more precise action in cellular regulation, without masking visible symptoms.
According to the article in Nature Communications, the combination of cellular and clinical measures strengthens the evidence that epoxy-oxylipins act as an intrinsic control mechanism. For Derek Gilroy, the possibility of repurposing a suitable drug for human use expands the potential for clinical application.
Clinical Implications for Rheumatoid Arthritis and Cardiovascular Diseases
The authors see room to test sEH inhibitors in rheumatoid arthritis and cardiovascular diseases, alone or combined with current therapies. Olivia Bracken explained that the strategy may help prevent or delay joint damage by modulating inflammation without turning off the entire immune response.
This perspective is especially relevant in crises of chronic inflammatory conditions, an area lacking effective options, according to UCL. Clinical trials will be able to evaluate dosage, administration timing, and safety across different patient profiles.
Team, Funding, and Relevance to Chronic Pain
The study involved researchers from UCL, King’s College London, University of Oxford, Queen Mary University of London, and National Institute of Environmental Health Sciences in the United States. Funding came from Arthritis UK, an organization focused on research in musculoskeletal diseases.
According to Caroline Aylott from Arthritis UK, arthritis pain affects how people move, think, sleep, and relate to others. She advocates for increasing investments to understand the mechanisms that modulate pain, as the experience varies from person to person.
By identifying a natural process capable of interrupting inflammation and pain, the research offers a promising path to improve quality of life. On February 22, 2026, UOL VivaBem highlighted these findings based on a statement from UCL and the scientific article.
Do you agree that modulating sEH and increasing epoxy-oxylipins could be a safer alternative to traditional anti-inflammatory drugs? Do you believe that a treatment that does not alter redness and swelling but reduces pain and inflammatory cells is sufficient in acute crises? Leave your comment and tell where this discovery could make a bigger difference in managing chronic inflammation.
-
1 person reacted to this.